{"organizations": [], "uuid": "ed227d7a7afa64118697318f3ba9411be6687e01", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-pulmatrix-announces-acceptance-of/brief-pulmatrix-announces-acceptance-of-a-clinical-trial-application-in-europe-for-pulmazole-idUSASB0C1QA", "country": "US", "domain_rank": 408, "title": "BRIEF-Pulmatrix Announces Acceptance Of A Clinical Trial Application In Europe For Pulmazole", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-22T19:59:00.000+02:00", "replies_count": 0, "uuid": "ed227d7a7afa64118697318f3ba9411be6687e01"}, "author": "", "url": "https://www.reuters.com/article/brief-pulmatrix-announces-acceptance-of/brief-pulmatrix-announces-acceptance-of-a-clinical-trial-application-in-europe-for-pulmazole-idUSASB0C1QA", "ord_in_thread": 0, "title": "BRIEF-Pulmatrix Announces Acceptance Of A Clinical Trial Application In Europe For Pulmazole", "locations": [], "entities": {"persons": [{"name": "clinica", "sentiment": "negative"}], "locations": [{"name": "europe", "sentiment": "none"}, {"name": "europe", "sentiment": "none"}], "organizations": [{"name": "pulmatrix inc", "sentiment": "none"}, {"name": "pulmazole reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 22, 2018 / 6:00 PM / Updated 4 minutes ago BRIEF-Pulmatrix Announces Acceptance Of A Clinical Trial Application In Europe For Pulmazole Reuters Staff 1 Min Read \nJan 22 (Reuters) - Pulmatrix Inc: \n* PULMATRIX ANNOUNCES ACCEPTANCE OF A CLINICAL TRIAL APPLICATION IN EUROPE FOR PULMAZOLE - AN INHALED DRY-POWDER ISPERSEâ„¢ FORMULATION OF ITRACONAZOLE \n* PULMATRIX INC - EXPECTS THAT TOP LINE RESULTS FOR PUR1900 STUDY WILL BE AVAILABLE IN MID-2018 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-22T19:59:00.000+02:00", "crawled": "2018-01-22T20:12:46.000+02:00", "highlightTitle": ""}